Diskoid Lupus Eritematozus Hastalarının Klinikoepidemiyolojik Profili ve Sistemik Hastalıklarla İlişkisi
Amaç: Lupus eritematozus (LE), kütanöz ve sistemik tipleri olan otoimmun bir hastalıktır. Diskoid LE (DLE), en sık görülenkutanöz formudur. DLE lezyonlarının çoğu güneş gören yerlerde lokalizedir.DLE hastalarının %5-30’u sistemik LE (SLE)’ye ilerleyebilmektedir. Bu nedenle, DLE hastaları SLE bulguları açısındandikkatlice değerlendirilmelidir.Gereç ve Yöntemler: Çalışmaya 2004-2020 yılları arasında, 18 yaş üzeri 67 DLE hastası dahil edildi. Hastaların demografikbilgileri, eşlik eden hastalıkları ve kan değerleri kaydedildi. Hamileler çalışma dışında bırakıldı.Veriler SPSS 25.0 programıyla analiz edildi. Kategorik veriler, Pearson ki-kare testi (gerektiğinde Fischer’ın kesin testi),kantitatif veriler bağımsız T-testi ile değerlendirildi.Bulgular: Çalışmada, yaş ortalamaları 41.94±13.85 olan 23 kadın (34.3%), 44 erkek (65.7%) hasta bulunmaktaydı. ANApozitifliği, benekli tarzda ANA pozitifliği, SS-A pozitifliği ve otoimmun hastalık öyküsünün anlamlı bir şekilde SLE’yeilerleme ile ilişkili olduğu görüldü (sırasıyla p:0,024; 0,007; 0,000; 0,021).Sonuç: Generalize lezyonlar, ANA pozitifliği, eklem ağrısı, anemi, lökopeni, trombositopeni ve artmış sedimentasyon hızıgibi bulguların SLE’ye ilerleyen hastaların tespitinde yardımcı rol oynadığı düşünülmektedir. Çalışmamızda otoimmunhastalık öyküsü, ANA (özellikle benekli tipte) ve SS-A pozitifliğinin SLE’ye ilerleme ile ilişkili olduğu gösterilmiştir.SLE’ye ilerleme konusunda dikkat edilmesi gereken özelliklerin bilinmesiyle, riskli hastaların tespiti ve yakın takibininsağlanabileceğini düşünmekteyiz.
Clinicoepidemiologic profile of Discoid Lupus Erythematosus and Its Relationship with Systemic Diseases
Aim: Lupus erythematosus (LE) is an autoimmune disease with cutaneous and systemic forms. Discoid lupus erythematosus(DLE) is the most common type of cutaneous LE. The majority of DLE lesions are localized in the sun-exposed areas.DLE patients may progress to systemic LE (SLE) with a range of 5-30%. Therefore, patients with DLE should be monitoredcarefully in terms of SLE findings.Materials and Methods: Sixty-seven patients with DLE aged above 18 years were included in the study, between theyears of 2004 and 2020. Demographic data, accompanying diseases, and blood values were recorded. Pregnant womenwere not included in the study.Data were analyzed with SPSS 25.0 program. Pearson's chi-square test (and Fischer's exact test when relevant) was usedfor the analysis of categorical variables, and independent sample T-test for quantitative variables.Results: The study included 23 women (34.3%) and 44 men (65.7%) with a mean age of 41.94±13.85 years. We found thatantinuclear antibody (ANA) positivity, speckled patern ANA, SS-A positivity, and a history of autoimmune disease weresignificantly related to SLE progression (p:0,024; 0,007; 0,000; 0,021, respectively).Conclusion: Generalized lesions, ANA positivity, joint pain, anemia, leukopenia, thrombocytopenia, and increasedsedimentation rates are considered to be indicative of SLE progression. We found that a history of autoimmune disease, ANA(especially speckled pattern) positivity, and SS-A positivity may be related to SLE progression. We think that being aware ofthe predictive features for the SLE progression will enable determining risky patients and monitoring them closely.
___
- 1. Ji YZ, Mei XL, Wei FL, Liu SR, Ji YB. A secondary discoid lupus
erythematosus induced by scald of edible oil: An illustration of
Koebner phenomenon. J Cosmet Dermatol. 2020; 19 :1699-701.
- 2. Zhou W, Wu H, Zhao M, Lu Q. New insights into the progression
from cutaneous lupus to systemic lupus erythematosus. Expert
Rev Clin Immunol. 2020; 16: 829-37.
- 3. Grönhagen CM, Nyberg F. Cutaneous lupus erythematosus: An
update. Indian Dermatol Online J. 2014; 5: 7-13.
- 4. Uva L, Miguel D, Pinheiro C, Freitas JP, Marques Gomes M, Filipe
P. Cutaneous manifestations of systemic lupus erythematosus.
Autoimmune Dis. 2012; 2012: 834291.
- 5. Yavuz GO, Yavuz IH, Bayram I, Aktar R, Bilgili SG. Clinic experience
in discoid lupus erythematosus: a retrospective study of 132
cases. Postepy Dermatol Alergol. 2019; 36: 739-43.
- 6. Lenormand C, Lipsker D. Lupus erythematosus: Significance of
dermatologic findings. Ann Dermatol Venereol. 2021; 148: 6-15.
- 7. Little AJ, Vesely MD. Cutaneous Lupus Erythematosus: Current and
Future Pathogenesis-Directed Therapies. Yale J Biol Med. 2020; 93:81-95.
- 8. Chanprapaph K, Tankunakorn J, Suchonwanit P, Rutnin S.
Dermatologic Manifestations, Histologic Features and Disease
Progression among Cutaneous Lupus Erythematosus Subtypes:
A Prospective Observational Study in Asians. Dermatol Ther
(Heidelb). 2021; 11: 131-47.
- 9. Cooper EE, Pisano CE, Shapiro SC. Cutaneous Manifestations
of "Lupus": Systemic Lupus Erythematosus and Beyond. Int J
Rheumatol. 2021; 2021: 6610509.
- 10. Wieczorek IT, Propert KJ, Okawa J, Werth VP. Systemic
Symptoms in the Progression of Cutaneous to Systemic Lupus
Erythematosus. JAMA Dermatol. 2014; 150: 291–6.
- 11. McDaniel B, Sukumaran S, Koritala T, Tanner LS. Discoid Lupus
Erythematosus. [Updated 2021 Dec 6]. In: StatPearls [Internet].
Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available
from: https://www.ncbi.nlm.nih.gov/books/NBK493145/.
(28.01.2022’de alınmıştır)
- 12. Insawang M, Kulthanan K, Chularojanamontri L, Tuchinda
Papapit, Pinkaew S. Discoid lupus erythematosus: description of
130 cases and review of their natural history and clinical course.
J Clin Immunol Immunopathol Res. 2010; 2: 1-8.
- 13. Callen JP. Cutaneous lupus erythematosus: a personal approach
to management. Australas J Dermatol. 2006; 47: 13-27.
- 14. Kim A, Chong BF. Photosensitivity in cutaneous lupus
erythematosus. Photodermatol Photoimmunol Photomed.
2013; 29: 4-11.
- 15. Sanders CJ, Van Weelden H, Kazzaz GA, et al. Photosensitivity in
patients with lupus erythematosus: a clinical and photobiological
study of 100 patients using a prolonged phototest protocol. Br J
Dermatol. 2003; 149: 131-7.
- 16. Kuhn A, Aberer E, Bata-Csörgő Z, et al. S2k guideline for
treatment of cutaneous lupus erythematosus - guided by the
European Dermatology Forum (EDF) in cooperation with the
European Academy of Dermatology and Venereology (EADV). J
Eur Acad Dermatol Venereol. 2017; 31: 389-404.
- 17. Lin TL, Wu CY, Juan CK, et al. Long-Term Risk of Autoimmune
Diseases other than Systemic Lupus Erythematosus in Cutaneous
Lupus Erythematosus-Alone Patients: A 10-Year Nationwide
Cohort Study. Dermatology. 2022; 238: 92-100.
- 18. Kunzler E, Hynan LS, Chong BF. Autoimmune Diseases in Patients With Cutaneous Lupus Erythematosus. JAMA Dermatol. 2018; 154: 712-6.
- 19. Shi KY, Kunzler E, Hynan LS, Chong BF. Autoimmune disease
development before and after cutaneous lupus erythematosus
diagnosis. Br J Dermatol. 2020; 182: 1309-10.
- 20. Bencze G, Lakatos L. Relationship of systemic lupus
erythematosus to rheumatoid arthritis, discoid lupus
erythematosus, and sjogren's syndrome a clinical study Ann
Rheum Dis. 1963; 22: 273-5.
- 21. Bencze G. Relationship of Systemic Lupus Erythematosus (SLE) to
Rheumatoid Arthritis (RA), Discoid Lupus Erythematosus (DLE)
and Sjögren's Syndrome: A Clinical Study. Scand J Rheumatol.
1987; 16: 191-6.
- 22. Enginar AU, Nur H, Kacar C. Coexistence of ankylosing spondylitis
and discoid lupus: A case report. North Clin Istanb. 2019; 6: 412-4.
- 23. Azarisman SM, Heselynn H. Systemic lupus erythematosus
presenting as parotitis and secondary Sjogren's syndrome.
Singapore Med J. 2007; 48: 60-1.
- 24. Singh AG, Crowson CS, Singh S, et al. Cancer risk in cutaneous
lupus erythematosus: a population-based cohort study.
Rheumatology (Oxford). 2016; 55: 2009-13.
- 25. Westermann R, Zobbe K, Cordtz R, Haugaard JH, Dreyer
L. Increased cancer risk in patients with cutaneous lupus
erythematosus and systemic lupus erythematosus compared
with the general population: A Danish nationwide cohort study.
Lupus. 2021; 30: 752-61.
- 26. Song L, Wang Y, Zhang J, et al. The risks of cancer development
in systemic lupus erythematosus (SLE) patients: a systematic
review and meta-analysis. Arthritis Res Ther. 2018; 20: 270.
- 27. Blake SC, Daniel BS. Cutaneous lupus erythematosus: A review
of the literature. Int J Womens Dermatol. 2019; 5: 320-9.
- 28. Grönhagen C, Fored C, Granath F, Nyberg F. Cutaneous lupus
erythematosus and the association with systemic lupus
erythematosus: A population-based cohort of 1088 patients in
Sweden. Br. J. Dermatol. 2011; 164: 1335–41.
- 29. Chong BF, Song J, Olsen NJ. Determining risk factors for
developing systemic lupus erythematosus in patients with
discoid lupus erythematosus. Br J Dermatol. 2012; 166: 29-35.
- 30. Bitar C, Menge TD, Chan MP. Cutaneous manifestations of
lupus erythematosus: a practical clinicopathological review for
pathologists. Histopathology. 2022; 80: 233-50.
- 31. Al-Saif FM, Al-Balbeesi AO, Al-Samary AI, et al. Discoid
lupus erythematosus in a Saudi population: Clinical and
histopathological study. JSSDDS. 2012; 16: 9-12.
- 32. Tang WYM, Chan LY, Lo KK. Discoid lupus erythematosus in
Hongkong Chinese: a review of 12 cases. HKMJ. 1996; 2: 239-45.
- 33. Prystowsky SD, Gilliam JN. Antinuclear antibody studies in
chronic cutaneous discoid lupus erythematosus. Arch Dermatol.
1977; 113: 183-6.
- 34. Böckle BC, Stanarevic G, Sepp NT. Detection of Ro/SS-A
antibodies in lupus erythematosus: what does it mean for the
dermatologist? J Am Acad Dermatol. 2013; 68: 385-94.
- 35. Oh EH, Kim EJ, Ro YS, Ko JY. Ten-year retrospective
clinicohistological study of cutaneous lupus erythematosus in
Korea. J Dermatol. 2018; 45: 436-43.